Table 2.
Week | Active (n=200) | Placebo (n=114) | ||||
---|---|---|---|---|---|---|
n | Percent | Cumulative Percent | n | Percent | Cumulative Percent | |
1 | 50 | 25.0 | 25.0 | 23 | 20.2 | 20.2 |
2 | 53 | 26.5 | 51.5 | 17 | 14.9 | 35.1 |
3 | 20 | 10.0 | 61.5 | 21 | 18.4 | 53.5 |
4 | 23 | 11.5 | 73.0 | 16 | 14.0 | 67.5 |
5 | 22 | 11.0 | 84.0 | 17 | 14.9 | 82.5 |
6 | 9 | 4.5 | 88.5 | 4 | 3.5 | 86.0 |
7 | 9 | 4.5 | 93.0 | 7 | 6.1 | 92.1 |
8 | 14 | 7.0 | 100.0 | 9 | 7.9 | 100.0 |
Participants who had clinically significant improvement (>=50% reduction in hot flash frequency) at any time in the 8-week study (n=314).